# Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis

> **NCT01450488** · PHASE2 · COMPLETED · sponsor: **AB Science** · enrollment: 35 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** masitinib
- **DRUG:** masitinib

## Key facts

- **NCT ID:** NCT01450488
- **Lead sponsor:** AB Science
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2007-07
- **Final completion:** 2010-01
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2018-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01450488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01450488, "Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01450488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*